Advertisement

Topics

Latest "MAQUET Cardiovascular LLC" News Stories

18:38 EDT 25th September 2018 | BioPortfolio

Here are the most relevant search results for "MAQUET Cardiovascular LLC" found in our extensive news archives from over 250 global news sources.

More Information about MAQUET Cardiovascular LLC on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about MAQUET Cardiovascular LLC for you to read. Along with our medical data and news we also list MAQUET Cardiovascular LLC Clinical Trials, which are updated daily. BioPortfolio also has a large database of MAQUET Cardiovascular LLC Companies for you to search.

Showing "MAQUET Cardiovascular" News Articles 1–25 of 2,800+

Tuesday 25th September 2018

TCT.18: Ultrasound-guided DES implantation yields better outcomes than angiography-guided surgery

Intravascular ultrasound (IVUS)-guided stent implantation offers improved clinical outcomes for heart patients over a traditional angiography-guided approach, researchers from China reported at this week’s Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Diego, California.


SweetLeaf® Urges ‘One Sweet Change’ to Family Meals in September

Studies show home-cooked meals benefit spirit, brain, health for all family members GILBERT, Ariz. (PRWEB) September 25, 2018 Wisdom Natural Brands, maker of the SweetLeaf® Stevia Sweetener family of products, encourages Americans to come together and share meals during September, which is National Family Meals Month. Many studies show that home-cooked meals nourish the spirit, brain and hea...

STAT Plus: A lot has to happen before Amarin establishes its Vascepa omega-3 capsules as the next cardiovascular blockbuster. When fuller data are presented at @American_Heart meeting Nov. 10, any "warts" in the study could be revealed. https://buff.ly/2I

STAT Plus: A lot has to happen before Amarin establishes its Vascepa omega-3 capsules as the next cardiovascular blockbuster. When fuller data are presented at @American_Heart meeting Nov. 10, any "warts" in the study could be revealed. https://buff.ly/2Ifzezl 


Eluvia vascular stent approved by FDA following IMPERIAL

The Eluvia drug-eluting vascular stent system has been approved by the FDA, device maker Boston Scientific announced Sept. 24—just two days after results from the IMPERIAL trial were presented at the Transcatheter Cardiovascular Therapeutics 2018 meeting.

TCT.18: ReCre8 finds polymer-free stent safe, effective for clinical use

A novel, polymer-free amphilius-eluting stent known as the “Cre8” was proven noninferior to the latest-generation permanent polymer drug-eluting stent in the first large-scale trial of its kind, according to research presented at the Cardiovascular Research Foundation’s 30th annual TCT conference in San Diego this week.

Lorcaserin does not increase rate of cardiovascular events in overweight or obese patients

1. At a median follow-up of 3.3 years, rates of composite cardiovascular events in at-risk overweight or obese patients treated with lorcaserin were not significantly worse than for placebo treated patients. 2. Lorcaserin treated patients had significantly greater weight loss at 1 year compared to placebo treated patients. Evidence Rating Level: 1 (Excellent)      Study Rundown: […]

Millendo Therapeutics Appoints Habib Dable to Its Board of Directors

Millendo Therapeutics, Inc., a clinical-stage biotechnology company developing novel therapies for orphan endocrine diseases, today announced the appointment of Habib Dable, President and Chief Executive Officer of Acceleron Pharma Inc., to the Company’s Board of Directors. “Habib brings to our board an exceptional mix of executive and ...

AstraZeneca’s Farxiga succeeds in phase 3 cardiovascular outcomes trial

Farxiga was assessed in a trial, dubbed DECLARE-TIMI 58, in more than 17,000 T2D adult patients having multiple CV risk factors or established CV condition. In the five-year The post AstraZeneca’s Farxiga succeeds in phase 3 cardiovascular outcomes trial appeared first on Pharma Business review.

Farxiga cuts hospitalisation for heart failure or CV death, study shows

AstraZeneca has unveiled new data showing a statistically-significant reduction in hospitalisation for heart failure or cardiovascular (CV) death in a broad population of patients with type II diabetes taking Farxiga.

Alucent Biomedical Announces Formation of Scientific Advisory Board

Alucent Biomedical, a privately held biotechnology company founded to transform the way vascular disease is treated, today announced the formation of its sci

GlycoMark®, Inc. Announces Partnership with Premier Medical Laboratory Services to Expand Diabetes Test Menu

GlycoMark has announced a partnership with Premier Medical Laboratory Services to increase the availability of the GlycoMark test, the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions in patients with diabetes. NEW YORK (PRWEB) September 25, 2018 GlycoMark®, Inc. has announced a partnership with Premier Medical Laboratory Services (PMLS) to ...

Fish Oil Drug May Reduce Heart Attack and Stroke Risks for Some

Large doses of an omega-3 fatty acid in fish oil sharply reduced the rate of cardiovascular events in people with a history of heart disease or Type 2 diabetes.

What's missing? Sometimes we look at a picture but miss the one thing that makes all the difference. #LetsCompleteThePicture and treat cardiovascular, renal, and metabolic (#CVRM) diseases collaboratively. #CaReMe - Read more: http://bit.ly/2QWn2aA pi

What's missing? Sometimes we look at a picture but miss the one thing that makes all the difference. #LetsCompleteThePicture and treat cardiovascular, renal, and metabolic ( #CVRM) diseases collaboratively. #CaReMe - Read more: http://bit.ly/2QWn2aA  pic.twitter.com/vbM

Monday 24th September 2018

BioAlberta Recognizes Alberta Innovators and Entrepreneurs at 2018 Awards Gala

At its 2018 awards gala, BioAlberta, the province’s life sciences industry association, recognized two leaders for their innovation and achievements. BioAlberta congratulates Circle Cardiovascular Imaging Inc. for winning its Company of the Year award and Dr. John Lewis for winning its Scientific Achievement and Innovation Award. The Company of ...

The association between serum sodium concentration, hypertension and primary cardiovascular events: a retrospective cohort study

“This is absolutely the most significant study in the field of cardiovascular risk reduction since the statins were introduced.” https://buff.ly/2xzKHG0 

“This is absolutely the most significant study in the field of cardiovascular risk reduction since the statins were introduced.” https://buff.ly/2xzKHG0 

Venus Medtech Launches Global Advisory Board to Target for International Market

SAN DIEGO, Sept. 25, 2018 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc., a Chinese medical device company specializing in transcatheter valve replacement therapy, has retained four world-renowned experts specialized in interventional cardiovascular to form a Global Advisory Board. The Board members will contribute their insights to Venus Medtech on global innovation of interventional car...

'That's Huge, Folks:' Amarin's Vascepa Cuts CV Risk By 25% On Top Of Statins

Cardiovascular outcomes data exceeded expectations for the fish oil pill, vindicating Amarin, which has fought long and hard for Vascepa's...   

AstraZeneca reports positive data from type 2 diabetes Phase III trial

AstraZeneca has reported positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) of Farxiga (dapagliflozin) against...Read More... The post AstraZeneca reports positive data from type 2 diabetes Phase III trial appeared first on Drug Development Technology.

CathWorks FFRangio™ Trial Meets Primary Endpoint and Exceeds Performance Goals

Trial Results Published in Circulation The journal Circulation published results from the CathWorks FFRangio™ FAST-FFR clinical trial in an article titled Accuracy of Fractional Flow Reserve Derived From Coronary Angiography. The publication and trial results were announced today at the 2018 TCT (Transcatheter Cardiovascular Therapeutics) annual meet...

Exercise training and/or diet on reduction of intra-abdominal adipose tissue and risk factors for cardiovascular disease

Novel radiopaque stent offers better x-ray visibility

Results from the BIONYX Trial found the Resolute Onyx stent provided better x-ray visibility compared to Orsiro, an established cobalt-chromium strut stent, according to findings presented Monday, Sept. 24, at the Transcatheter Cardiovascular Therapeutics (TCT) symposium in San Diego.

Omega-3 Pill Prevents CV Events in High-Risk Patients

The omega-3 pill Vascepa (icosapent ethyl) — approved to treat very high triglyceride levels — significantly lowered the risk for cardiovascular events in statin-treated patients...

What's missing? Sometimes we look at a picture but miss the one thing that makes all the difference. #LetsCompleteThePicture and treat cardiovascular, renal, and metabolic (#CVRM) diseases collaboratively. #CaReMe Read more: http://bit.ly/2py3AEV pic.

What's missing? Sometimes we look at a picture but miss the one thing that makes all the difference. #LetsCompleteThePicture and treat cardiovascular, renal, and metabolic ( #CVRM) diseases collaboratively. #CaReMe Read more: http://bit.ly/2py3AEV  pic.twitter.com/GpqkMLifJ0

Landmark Lipid-Rich Plaque (LRP) Study Results Demonstrate the Ability to Accurately Identify Patients and Plaques at Risk for Major Coronary Events

Study successfully demonstrated endpoints of identifying both vulnerable patients and vulnerable plaques that are at significantly higher risk for subsequent major adverse cardiovascular events Infraredx, Inc., a pioneer in intravascular imaging for mapping coronary artery disease, presented late-breaking clinical trial results for its landmark Lipid-R...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks